Fig. 5: Alluvial plot illustrating changes in PPM-guided stratification due to lanabecestat treatment in the AMARANTH trial. | Nature Communications

Fig. 5: Alluvial plot illustrating changes in PPM-guided stratification due to lanabecestat treatment in the AMARANTH trial.

From: AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial

Fig. 5

Percentage of patients in each treatment group (placebo, lanabecestat 20 mg, lanabecestat 50 mg) transitioning between PPM-stratified groups (slow vs. rapid progressive) from baseline to week 104. There is a reduction in the percentage of patients transitioning from the slow progressive group (red) at baseline to the rapid progressive group (green) at week 104 compared to placebo. Conversely, there is an increase in the percentage of patients transitioning from the rapid progressive group at baseline to the slow progressive at week 104 compared to placebo. Source data are provided as a Source Data file.

Back to article page